NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $238,000 | -2.1% | 13,426 | -5.9% | 0.00% | 0.0% |
| Q1 2021 | $243,000 | +27.9% | 14,269 | +27.4% | 0.00% | – |
| Q4 2020 | $190,000 | +313.0% | 11,199 | +300.0% | 0.00% | – |
| Q3 2020 | $46,000 | +1050.0% | 2,800 | +1397.3% | 0.00% | – |
| Q4 2019 | $4,000 | -99.8% | 187 | -99.9% | 0.00% | -100.0% |
| Q3 2019 | $2,445,000 | -50.9% | 134,236 | -4.1% | 0.01% | -64.7% |
| Q2 2019 | $4,980,000 | +6.7% | 139,959 | +0.8% | 0.02% | 0.0% |
| Q1 2019 | $4,666,000 | +2.6% | 138,880 | +0.4% | 0.02% | -10.5% |
| Q4 2018 | $4,547,000 | -41.5% | 138,341 | +8.5% | 0.02% | -32.1% |
| Q3 2018 | $7,774,000 | -51.1% | 127,524 | -60.8% | 0.03% | +3.7% |
| Q2 2018 | $15,889,000 | – | 325,393 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |